OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Metastatic breast cancer"

The results of a phase III study ( Study 301 ) of Eribulin mesylate ( Halaven ) versus Capecitabine ( Xeloda ) in locally advanced or metastatic breast cancer were presented at the 2012 CTRC-AACR San ...


Pfizer has announced that the randomized Phase 2 trial, PALOMA-1, of Palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pro ...


Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. TH3RESA trial has compared Trastuzumab E ...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy ( Trastuzumab [ Herceptin ] and Lapatinib [ Tykerb ] ) ...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free ...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate ( ADC ) was evaluated in patients with HER2-positive, un ...


The CDK4/6 inhibitor Palbociclib ( Ibrance ) in combination with Letrozole ( Femara ) has become a standard first-line treatment for patients with luminal metastatic breast cancer ( MBC ) ( PALOMA-1 & ...


Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor (PR)- breast cancer. The functional role of androgen ...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival ( IDFS ), significantly decreasing the risk of breast c ...